11/12/2024 1:34 PM | Corbus Pharmaceuticals (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024 8:37 AM | Adage Capital Management, L.P. (Filed by) Corbus Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024 3:58 PM | Corbus Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/07/2024 7:41 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/04/2024 10:28 AM | Corbus Pharmaceuticals (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/04/2024 6:51 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/22/2024 5:06 PM | BlackRock, Inc. (Filed by) Corbus Pharmaceuticals (Subject)
| Form SC 13G | |
|
10/15/2024 3:19 PM | Corbus Pharmaceuticals (Subject) MILLENNIUM MANAGEMENT LLC (Filed by)
| Form SC 13G/A | |
09/24/2024 3:04 PM | Chen Bihua (Reporting) Corbus Pharmaceuticals (Issuer) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/04/2024 3:44 PM | CATLIN AVERY W (Reporting) Corbus Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/03/2024 3:52 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/20/2024 3:45 PM | Corbus Pharmaceuticals (Issuer) Kung Winston (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
08/20/2024 3:48 PM | Corbus Pharmaceuticals (Issuer) Kung Winston (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/20/2024 7:15 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/06/2024 3:42 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/18/2024 4:58 PM | Cohen Yuval (Reporting) Corbus Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 4:59 PM | Corbus Pharmaceuticals (Issuer) Moran Sean F. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 8:21 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/14/2024 4:25 PM | Cohen Yuval (Reporting) Corbus Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/14/2024 4:25 PM | Corbus Pharmaceuticals (Subject) Moran Sean F. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/03/2024 3:30 PM | Corbus Pharmaceuticals (Issuer) Salzmann Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/03/2024 3:31 PM | CATLIN AVERY W (Reporting) Corbus Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/03/2024 3:32 PM | Corbus Pharmaceuticals (Issuer) Jenkins John Kenneth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/03/2024 6:08 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/31/2024 3:39 PM | Corbus Pharmaceuticals (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/20/2024 3:30 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/09/2024 7:00 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/07/2024 7:30 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/11/2024 8:17 AM | Corbus Pharmaceuticals (Issuer) Moran Sean F. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/10/2024 3:58 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/10/2024 3:59 PM | Corbus Pharmaceuticals (Filer)
| Form DEFA14A | |
03/22/2024 4:05 PM | Corbus Pharmaceuticals (Filer)
| Form PRE 14A | |
03/20/2024 11:15 PM | Corbus Pharmaceuticals (Filer)
| Form EFFECT | |
03/20/2024 4:07 PM | Corbus Pharmaceuticals (Filer)
| Form 424B3 | |
03/20/2024 4:10 PM | Corbus Pharmaceuticals (Filer)
| Form 10-K/A | |
03/20/2024 4:13 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/13/2024 3:52 PM | Corbus Pharmaceuticals (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
03/12/2024 4:19 PM | Corbus Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/12/2024 7:15 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/11/2024 4:34 PM | Chen Bihua (Reporting) Corbus Pharmaceuticals (Issuer) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 4:13 PM | Corbus Pharmaceuticals (Issuer) Smethurst Dominic (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Trump’s Back, but DC’s Coming for Your Money! (Ad) Trump's back in the White House, ready to hit the gas on America's comeback.
He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs.
But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov |
02/29/2024 4:07 PM | Corbus Pharmaceuticals (Issuer) Smethurst Dominic (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
02/14/2024 3:45 PM | Corbus Pharmaceuticals (Subject) K2 HealthVentures Equity Trust LLC (Filed by)
| Form SC 13G/A | |
02/14/2024 2:19 PM | Cohen Yuval (Reporting) Corbus Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2024 2:26 PM | Corbus Pharmaceuticals (Issuer) Moran Sean F. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 3:47 PM | Corbus Pharmaceuticals (Subject) Cormorant Global Healthcare Master Fund, LP (Filed by)
| Form SC 13G | |
02/05/2024 7:12 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/01/2024 7:55 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K/A | |
02/01/2024 4:27 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/01/2024 4:09 PM | Corbus Pharmaceuticals (Filer)
| Form 424B5 | |
01/31/2024 8:16 AM | Corbus Pharmaceuticals (Filer)
| Form S-3MEF | |
01/30/2024 7:40 PM | Corbus Pharmaceuticals (Filer)
| Form 424B5 | |
01/30/2024 7:41 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/30/2024 5:07 PM | Corbus Pharmaceuticals (Issuer) HOLMER ALAN F (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 3:56 PM | Cohen Yuval (Reporting) Corbus Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 3:18 PM | Chen Bihua (Reporting) Corbus Pharmaceuticals (Issuer) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/30/2024 3:23 PM | Chen Bihua (Reporting) Corbus Pharmaceuticals (Issuer) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2024 3:40 PM | Corbus Pharmaceuticals (Subject) Point72 Asset Management, L.P. (Filed by)
| Form SC 13G | |
01/29/2024 6:30 AM | Corbus Pharmaceuticals (Filer)
| Form 424B3 | |
01/29/2024 6:31 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/09/2024 7:45 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |